An interventional study of AB Temporal Interference Stimulation and BA Temporal Interference Stimulation in Parkinson's Disease and Parkinsonian Syndromes, sponsored by Ruijin Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Parkinson Disease by Ruijin Hospital — 8 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · Ruijin Hospital.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is one of 16 with no phase, and was the 18th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →8 of the 20 studies in Parkinson Disease by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 50–85
Ruijin Hospital · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 40–65
Ruijin Hospital · Sites in China
Ruijin Hospital · Sites in China
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 29 across the 18 interventional studies, 360 across the 2 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
2 of the studies in Parkinson Disease by Ruijin Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07353463Ruijin HospitalShanghai Clinical Cohort - Parkinson's Disease (Reserve) | 2026-12-31 |
| NCT07774312Ruijin HospitalSTN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Parkinson Disease by Ruijin Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to explore the therapeutic effects of noninvasive deep brain electrical stimulation using temporal interference principles (Temporal Interference Stimulation, TIS) on both motor and non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes, and to investigate strategies for optimal stimulation target selection. A prospective, single-center, double-blind, randomized, crossover design will be implemented. Participants will be recruited from outpatient and inpatient departments of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The primary hypothesis is that TIS will significantly improve motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The primary outcome measure will be the change in the MDS-UPDRS Part III score from baseline to post-stimulation.
This study is expected to provide direct evidence supporting the clinical application and target selection strategies of noninvasive deep brain stimulation for the treatment of Parkinson's disease and Parkinsonian syndromes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with PD or PDS receive TIS targeting the contralateral globus pallidus internus (GPi). Each group consists of 10 patients with PD and 10 patients with PDS.
Device: AB Temporal Interference Stimulation · Device: BA Temporal Interference Stimulation
Participants with PD or PDS receive TIS targeting the contralateral subthalamic nucleus (STN). Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Device: AB Temporal Interference Stimulation · Device: BA Temporal Interference Stimulation
Participants with PD or PDS receive TIS targeting the contralateral putamen. Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Device: AB Temporal Interference Stimulation · Device: BA Temporal Interference Stimulation
Participants with PD or PDS receive TIS targeting the contralateral lateral hypothalamic area (LHA). Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Device: AB Temporal Interference Stimulation · Device: BA Temporal Interference Stimulation
Participants with PD or PDS receive TIS targeting the ipsilateral cerebellar dentate nucleus. Each group consists of 10 patients with PD and 10 patients with Parkinsonian syndromes.
Device: AB Temporal Interference Stimulation · Device: BA Temporal Interference Stimulation
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with AB sequence (Active → Sham). Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz; Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz.
Participants with PD or PDS receive TIS. Each session lasts 30 minutes for 3 consecutive days. The study uses a crossover design with BA sequence (Sham → Active). Sham stimulation: current 1.5-4 mA, carrier frequency 2000 Hz, frequency offset 0 Hz. Active stimulation: current 1.5-4 mA (patient's maximum tolerated), carrier frequency 2000 Hz, frequency offset 130 Hz;
Efficacy of temporal interference stimulation (TIS) on motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The MDS-UPDRS Part III is a rater-administered motor examination used to evaluate the severity of motor impairment in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 132, with lower scores indicating less severe motor symptoms. Changes from baseline after real or sham stimulation will be analyzed and compared between groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Secondary motor outcome
The UMSARS is a rater-administered scale used to assess disease severity in patients with Parkinsonian syndromes, particularly multiple system atrophy. The total score ranges from 0 to 104, with a higher score indicating greater disease severity. The change in UMSARS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Secondary motor outcome
The Freezing of Gait Questionnaire is used to assess the severity and frequency of freezing of gait in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 24, with a higher score indicating more severe freezing of gait. The change in FOGQ score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Secondary motor outcome
The Berg Balance Scale is a rater-administered scale used to assess balance function and fall risk. The total score ranges from 0 to 56, with a higher score indicating better balance function. The change in Berg Balance Scale score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Hamilton Anxiety Rating Scale-14(HAMA-14)is a rater-administered scale used to assess the severity of anxiety symptoms. The total score ranges from 0 to 56, with a higher score indicating more severe anxiety. The change in HAMA-14 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Hamilton Depression Rating Scale-17(HAMD-17)is a rater-administered scale used to assess the severity of depressive symptoms. The total score ranges from 0 to 52, with a higher score indicating more severe depression. The change in HAMD-17 score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Mini-Mental State Examination(MMSE)is a brief cognitive screening scale used to assess global cognitive function. The total score ranges from 0 to 30, with a higher score indicating better cognitive function. The change in MMSE score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Montreal Cognitive Assessment(MoCA)is a brief cognitive screening scale used to assess global cognitive function, particularly mild cognitive impairment. The total score ranges from 0 to 30, with a higher score indicating better cognitive function. The change in MoCA score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Non-Motor Symptoms Scale(NMSS)is a rater-administered scale used to assess the severity and frequency of non-motor symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 360, with a higher score indicating a greater non-motor symptom burden. The change in NMSS score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on non-motor symptoms in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction(SCOPA-AUT)is a patient-reported scale used to assess autonomic symptoms in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 69, with a higher score indicating more severe autonomic dysfunction. The change in SCOPA-AUT score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The Parkinson's Disease Questionnaire-39 Summary Index(PDQ-39 SI)is a patient-reported scale used to assess health-related quality of life in patients with Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 100, with a higher score indicating poorer quality of life. The change in PDQ-39 SI score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The MDS-UPDRS Part I is used to assess non-motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 52, with a higher score indicating more severe non-motor symptom burden. The change in MDS-UPDRS Part I score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Efficacy of TIS on quality of life in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
The MDS-UPDRS Part II is used to assess motor experiences of daily living in patients with idiopathic Parkinson's disease and Parkinsonian syndromes. The total score ranges from 0 to 52, with a higher score indicating greater motor-related impairment in daily living. The change in MDS-UPDRS Part II score from baseline to after stimulation will be compared between the real and sham stimulation groups.
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Changes in resting-state EEG β-band oscillation power before and after stimulation
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Potential mechanisms underlying the therapeutic effects of TIS in patients with idiopathic Parkinson's disease and Parkinsonian syndromes
Changes in whole-brain resting-state fMRI functional connectivity strength, with exploratory analyses focusing on the sensorimotor and basal ganglia networks, before and after stimulation
Time frame: Baseline, 3 days after sham stimulation, and 3 days after active stimulation.
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
The number and severity of all AEs and SAEs will be collected and monitored throughout the study to evaluate the safety and tolerability of the intervention.
Time frame: From baseline through study completion (up to 3 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Sep 2026, 2 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 2 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.